Efavirenz Composition to Block Alpha-Synuclein Spread

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for synucleinopathies, such as Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy, primarily focus on symptom relief rather than disease progression, and long-term use can lead to debilitating side effects, with no known drugs effectively preventing the transmission and aggregation of alpha-synuclein.

Innovation Solution

A composition comprising efavirenz, a non-nucleoside reverse transcriptase inhibitor, is used to hinder cell-to-cell transmission and prevent intracellular aggregation of alpha-synuclein, thereby addressing the underlying causes of these diseases.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If current treatments for synucleinopathies are used to relieve symptoms, then symptom management is improved, but debilitating side effects increase and disease progression is not prevented

Engineering Contradiction:

Improvesymptom reliefVSAvoidside effects

Core Design Contradiction:

Ease of operationVSObject-affected harmful factors

Solution Approach 1:

The patent applies this principle by using efavirenz, an antiretroviral drug originally designed for HIV treatment, and repurposing it for synucleinopathies. The drug's known mechanism of inhibiting reverse transcriptase is leveraged to inhibit alpha-synuclein aggregation and transmission, converting a drug with established safety profiles into a therapeutic agent for a completely different disease class, thereby achieving symptom management without the debilitating side effects associated with current Parkinson's treatments

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

2Duration of action of stationary object

If long-term use of current treatments is continued to manage symptoms, then symptom control is maintained, but debilitating side effects worsen

Engineering Contradiction:

Improvetreatment durationVSAvoidside effects

Core Design Contradiction:

Duration of action of stationary objectVSObject-affected harmful factors

Solution Approach 1:

The patent applies this principle by utilizing efavirenz, a drug with a well-established safety profile from decades of HIV treatment use. The extensive clinical data from its long-term use in HIV patients provides a foundation for understanding its safety and tolerability, allowing for extended treatment durations in synucleinopathies without the unknown long-term side effects that plague current Parkinson's medications

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Reliability

If no drug is used to prevent alpha-synuclein transmission, then current symptom management continues, but disease progression is not halted

Engineering Contradiction:

Improvesymptom managementVSAvoiddisease progression prevention

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The patent applies this principle by using efavirenz to prevent alpha-synuclein aggregation and cell-to-cell transmission before these processes can lead to irreversible neuronal damage and disease progression. The drug interferes with the early stages of synucleinopathy pathogenesis, stopping the spread of pathological alpha-synuclein between cells before it can cause widespread neuronal death and permanent functional impairment

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS12521398B2Composition for treating synucleinopathies

Publication Date: 2026.01.13 STANDIGM

AI summary

A composition for preventing or treating synucleinopathies, which includes efavirenz or a salt or solvate thereof and a pharmaceutically acceptable carrier, is provided. The composition is useful in preventing or treating synucleinopathies, such as Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy, because the composition serves to hinder cell-to-cell transmission of alpha-synuclein, prevent intracellular aggregation of α-synuclein, and inhibit transmission of aggregated α-synuclein.